Literature DB >> 10829995

Newer anti-epileptic drugs.

S Aneja1, R W Newton.   

Abstract

During the past few years, a number of drugs have been added to the anti-epileptic arsenal. This review focusses on five of these drugs which have undergone extensive trials: Vigabatrin, Lamotrigine, Gabapentin, Felbamate and Oxcarbazepine. Some of these antiepileptic drugs appear to be helpful for treatment of catastrophic childhood epilepsies. Vigabatrin appears promising in children with infantile spasms who do not respond to ACTH or Prednisolone. Children with Lennox-Gastaut syndrome may respond to treatment with Lamotrigine or Vigabatrin. Gabapentin and vigabatrin have proved to be effective in refractory partial seizures. Oxcarbazepine, a ketoderivative of carbamazepine, is as effective as Carbamazepine but has a better safety profile. Lesser neurotoxicity and fewer drug interactions is another advantage with these drugs. However monitoring is required to determine the long term safety with their usage. These drugs have a definite role in childhood epilepsies refractory to conventional antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10829995     DOI: 10.1007/bf02845250

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  30 in total

Review 1.  Lamotrigine.

Authors:  M J Brodie
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

2.  Lamotrigine for intractable childhood epilepsy: a preliminary communication.

Authors:  J Gibbs; R E Appleton; L Rosenbloom; W C Yuen
Journal:  Dev Med Child Neurol       Date:  1992-04       Impact factor: 5.449

3.  Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy.

Authors:  J P Mumford; M Dam
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  Coadministration of vigabatrin and valproate in children with refractory epilepsy.

Authors:  J A Armijo; R Arteaga; E M Valdizán; J L Herranz
Journal:  Clin Neuropharmacol       Date:  1992-12       Impact factor: 1.592

5.  Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study.

Authors:  M Feucht; S Brantner-Inthaler
Journal:  Epilepsia       Date:  1994 Sep-Oct       Impact factor: 5.864

Review 6.  Vigabatrin. Clinical pharmacokinetics.

Authors:  E Rey; G Pons; G Olive
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

7.  Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin).

Authors:  L Gram; A Sabers; O Dulac
Journal:  Epilepsia       Date:  1992       Impact factor: 5.864

8.  Cross-reactive skin eruption with both carbamazepine and oxcarbazepine.

Authors:  R G Beran
Journal:  Epilepsia       Date:  1993 Jan-Feb       Impact factor: 5.864

9.  Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial.

Authors:  J Messenheimer; R E Ramsay; L J Willmore; R F Leroy; J J Zielinski; R Mattson; J M Pellock; A M Valakas; G Womble; M Risner
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

10.  Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures.

Authors:  G J Schapel; R G Beran; F J Vajda; S F Berkovic; M L Mashford; F M Dunagan; W C Yuen; G Davies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

View more
  1 in total

1.  Cerebellar atrophy in a child with valproate toxicity.

Authors:  Vidya B Ghosh; Seema Kapoor; Anjali Prakash; Sinchana Bhatt
Journal:  Indian J Pediatr       Date:  2011-01-19       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.